ESMO 2026 | NI-1801 with or without pembrolizumab in heavily pretreated ovarian cancer
Kaissa Ouali, MD, Institut Gustave Roussy, Villejuif, France, describes long-term overall survival with NI-1801, a mesothelin x CD47 bispecific antibody, as monotherapy and in combination with pembrolizumab in patients with mesothelin-expressing platinum-resistant epithelial ovarian cancer who had received four or more prior lines of therapy (NCT05403554). Monotherapy showed encouraging survival and a favorable safety profile, while the combination yielded notably enhanced survival not previously reported in this setting, particularly among responders. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Platinum-resistant ovarian carcinoma is where there is a real unmet need and we have a lot of new drugs that, by being specific, actually show activity, and particularly, probably, you know, we already presented the first data about this molecule last year at ESMO and showed that there is clinical activity in those patients who are heavily pre-treated in combination with pembrolizumab...
Platinum-resistant ovarian carcinoma is where there is a real unmet need and we have a lot of new drugs that, by being specific, actually show activity, and particularly, probably, you know, we already presented the first data about this molecule last year at ESMO and showed that there is clinical activity in those patients who are heavily pre-treated in combination with pembrolizumab. What we show here is that there is a clear benefit for those patients in the long term and probably I’m probably a little biased, but I think this drug will probably go into later development in this population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
